FDA Restarts Rulemaking To Establish Criteria For "Waived" CLIA Status
This article was originally published in The Gray Sheet
Executive Summary
FDA's Division for Clinical Laboratory Devices is planning to hold a public meeting this fall to discuss proposed criteria for categorizing laboratory tests as "waived" from Clinical Laboratory Improvement Act requirements, staffers report.
You may also be interested in...
FDA Prepares CLIA Guidances, Will Take Over CLIA Reviews In November
FDA will take the lead in reviewing Clinical Laboratory Improvement Act waiver applications and protocols, as well as complexity categorizations, starting Nov. 1.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.